Roche (OTCMKTS:RHHBY) Stock Rating Upgraded by Sanford C. Bernstein

Roche (OTCMKTS:RHHBY) was upgraded by research analysts at Sanford C. Bernstein to a “strong-buy” rating in a research report issued on Thursday,Zacks.com reports.

Roche Price Performance

Shares of RHHBY stock opened at $39.25 on Thursday. The stock’s 50-day simple moving average is $36.14 and its 200-day simple moving average is $38.25. Roche has a fifty-two week low of $29.20 and a fifty-two week high of $42.43. The company has a debt-to-equity ratio of 0.86, a current ratio of 1.26 and a quick ratio of 0.97.

Hedge Funds Weigh In On Roche

A number of large investors have recently bought and sold shares of the business. Verity Asset Management Inc. increased its stake in shares of Roche by 26.8% during the fourth quarter. Verity Asset Management Inc. now owns 8,036 shares of the company’s stock worth $280,000 after purchasing an additional 1,697 shares in the last quarter. Hantz Financial Services Inc. increased its stake in Roche by 0.9% during the 4th quarter. Hantz Financial Services Inc. now owns 33,708 shares of the company’s stock worth $1,176,000 after buying an additional 305 shares in the last quarter. Brooklyn Investment Group raised its holdings in shares of Roche by 36.6% during the fourth quarter. Brooklyn Investment Group now owns 1,354 shares of the company’s stock valued at $48,000 after acquiring an additional 363 shares during the last quarter. Diversified Trust Co lifted its position in shares of Roche by 1.2% in the fourth quarter. Diversified Trust Co now owns 60,453 shares of the company’s stock valued at $2,130,000 after acquiring an additional 711 shares in the last quarter. Finally, Bard Financial Services Inc. boosted its stake in shares of Roche by 37.7% in the fourth quarter. Bard Financial Services Inc. now owns 110,850 shares of the company’s stock worth $3,866,000 after acquiring an additional 30,350 shares during the last quarter.

About Roche

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.